SecBot SecBot
PRESS-RELEASE ·Filed Feb 18, 2026

IINN

Inspira Technologies
NEUTRAL
Impact 4/10
Horizonweeks Processed8mo ago Wirepress-3240229
Press release · Contract
Actionable Insight • Neutral

Monitor for future announcements regarding conversion of this evaluation into a commercial sale or expanded orders; follow-up deployments or contracts could signal growing market acceptance.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.5790
T+0 close · Feb 18, 2026 · via day close
Latest settled
−30.05%
T+60 · $0.4050
Vs SPY
−38.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 18 $0.5790entry
  2. T+1 · 9mo ago +0.17%α +0.41% · $0.5800
  3. T+5 · 9mo ago +1.90%α +0.89% · $0.5900
  4. T+20 · 8mo ago −3.28%α +0.31% · $0.5600
  5. T+60 · 6mo ago −30.05%α −38.24% · $0.4050
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inspira Technologies announced the deployment of its FDA-cleared ART100 system at a top-ranked academic medical center in New York for a structured commercial evaluation. This expands its presence in the U.S. Tier-1 hospital market, supporting its commercial strategy, though no financial terms or outcomes were disclosed.

Key Facts

  • Inspira Technologies deployed its ART100 system at a new U.S. academic medical center in New York.
  • The institution is ranked among New York State’s top 10 hospitals in Newsweek’s World’s Best Hospitals 2025.
  • The deployment is part of a structured commercial evaluation to assess clinical protocols and potential broader adoption.
  • No financial figures, revenue impact, or contractual terms were disclosed.
  • The ART100 is FDA-cleared for cardiopulmonary bypass in the U.S. and ECMO outside the U.S.

Financial Impact

No financial impact disclosed; no revenue, deal value, or guidance provided.

Risk Factors

  • Evaluation may not lead to commercial adoption.
  • No assurance of revenue generation from this deployment.
  • Forward-looking statements are subject to risks and uncertainties as outlined in the company's 20-F filing.

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3240229

US Market Status

Market Closed · Opens in 9h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026